[Treatment of advanced ovarian cancer: results of the Department of Clinical Pharmacology and Chemotherapy, N.N. Blokhin RORC from 1993-2010].
The aim of this study was to analyse the outcome of ovarian cancer depending on the type of surgical debulking, the strategy of treatment of recurrent cancer, and other clinical factors. We performed retrospective analysis of patients with stage IC-IV ovarian cancer treated at the Department of Clinical Pharmacology and Chemotherapy in 1993-2010. A total of 353 patients were included. The medians of progression-free and overall survival were 11.3 and 40.8 months respectively. The results of the treatment depended on the mode of surgical debulking, histological type and stage of the tumour, regimen of front-line chemotherapy. The main prognostic factor in recurrent ovarian cancer was the number of potentially effective anticancer agents used during the treatment.